<a href="https://laohu8.com/S/TEM">Tempus AI</a> revenue rises 84.7% to $334.2 million in third quarter 2025
Tempus AI Inc. reported third quarter 2025 revenue of $334.2 million, an increase of 84.7% from the same period in 2024. Gross profit rose 98.4% year-over-year to $209.9 million. The company reported a net loss of $80.0 million, compared to a net loss of $75.8 million in the third quarter of 2024. Genomics revenue reached $252.9 million, up 117.2% year-over-year. Tempus delivered 217,000 clinical tests in the quarter, representing 33% growth, with oncology and hereditary test volumes increasing by 27% and 37%, respectively. Insights bookings totaled $150 million, up 37.6% year-over-year. The company raised its full-year 2025 revenue guidance to $1.27 billion, indicating about 80% growth. Tempus ended the quarter with $764.3 million in cash and marketable securities. Business developments included expanding collaboration with Northwestern Medicine to integrate its generative-AI clinical co-pilot, acquiring Paige to strengthen digital pathology capabilities, and receiving FDA 510(k) clearances for RNA NGS and cardiac imaging platforms.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104178572) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.